Mathieu Latreille

Mathieu Latreille began their career in 2007 as a Postdoctoral Fellow at ETH Zürich, where they conducted research on characterizing regulatory microRNA circuits and their implications in type 1/2 diabetes and neuroendocrine disease, engineering and phenotyping of pre-clinical mouse models, and RNA:RNA and RNA:PRT interactions underlying miRNA target engagement and repression. In 2014, they became a Group Leader at the MRC London Institute of Medical Sciences and an Honorary Senior Lecturer at Imperial College London. In 2021, they joined Transine Therapeutics as the Director of Platform Development.

Mathieu Latreille completed their Bachelor of Science in Biotechnology from Université de Sherbrooke from 1996-1999. Mathieu then went on to pursue a Master of Science in Biochemistry from McGill University in Montréal, Canada from 2000-2002. Finally, they obtained their Doctor of Philosophy in Molecular Cell Biology and Genetics from McGill University in Montréal, Canada from 2003-2007.